

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.



February 13, 2026

Consolidated Financial Results for the Six Months Ended December 31, 2025 (Under Japanese GAAP)

Company name: Asahi Intecc Co., Ltd.
 Listing: Tokyo Stock Exchange and Nagoya Stock Exchange
 Securities code: 7747
 URL: <https://www.asahi-intecc.co.jp/>
 Representative: Kenji Miyata, President & CEO
 Inquiries: Mizuho Ito, Member of Board & CFO, General Manager of Administration
 Telephone: +81-561-56-1851
 Scheduled date of filing semi-annual report: February 13, 2026
 Scheduled date of commencing dividend payments: –
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended December 31, 2025 (from July 1, 2025 to December 31, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended								
December 31, 2025	71,266	15.9	24,372	40.1	24,143	43.5	17,214	40.4
December 31, 2024	61,491	13.2	17,395	28.9	16,821	24.9	12,261	24.9

Note: Comprehensive income For the six months ended December 31, 2025: ¥24,378 million (95.0%)
 For the six months ended December 31, 2024: ¥12,501 million (28.9%)

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
December 31, 2025	64.56	–
December 31, 2024	45.14	–

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Million yen	Million yen	%
December 31, 2025	195,870	158,671	80.6
June 30, 2025	193,187	151,354	77.9

Reference: Equity
 As of December 31, 2025: ¥157,775 million
 As of June 30, 2025: ¥150,558 million

2. Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
Fiscal year ended June 30, 2025	Yen –	Yen 0.00	Yen –	Yen 24.23	Yen 24.23
Fiscal year ending June 30, 2026	–	0.00			
Fiscal year ending June 30, 2026 (Forecast)			–	46.10	46.10

Note: Revisions to dividend forecasts announced most recently: Yes

Breakdown of year-end dividend for the fiscal year ending June 30, 2026 (forecast):

Ordinary dividend: 40.31 yen

Commemorative dividend: 5.79 yen

3. Consolidated financial results forecast for the fiscal year ending June 30, 2026 (July 1, 2025 to June 30, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	141,142	17.6	42,220	40.4	42,688	44.4	30,556	139.9	114.88

Note: Revisions to financial results forecast announced most recently: Yes

*** Notes**

(1) Significant changes in scope of consolidation during the period: None

Newly included: -

Excluded: -

(2) Accounting treatments adopted specially for the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	265,332,300 shares
As of June 30, 2025	271,633,600 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2025	7,977 shares
As of June 30, 2025	1,964,677 shares

(iii) Average number of shares during the period (cumulative)

Six months ended December 31, 2025	266,657,562 shares
Six months ended December 31, 2024	271,625,630 shares

* Semi-annual financial results reports are exempt from review by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

Financial results forecasts and other forward-looking statements provided in these materials are based on information available to the Company and certain other assumptions deemed reasonable as of the date of publication of this document, and do not represent any guarantee that the Company will achieve these results. Actual financial results and other aspects of business performance may differ significantly from these forecasts owing to various factors. Please refer to "1. Qualitative information on semi-annual financial results (3) Explanation of forecasts including consolidated results forecast" on page 3 of the attached materials for conditions forming the basis for financial results forecasts, notes regarding the use of financial results forecasts, and other information.

Table of contents of the attached materials

1. Qualitative information on semi-annual financial results	2
(1) Explanation of operating results	2
(2) Explanation of financial position	3
(3) Explanation of forecasts including consolidated results forecast	3
2. Semi-annual consolidated financial statements and major notes	4
(1) Semi-annual consolidated balance sheet	4
(2) Semi-annual consolidated statements of income and comprehensive income	6
Semi-annual consolidated statement of income	6
Semi-annual consolidated statement of comprehensive income	7
(3) Semi-annual consolidated statement of cash flows	8
(4) Notes to semi-annual consolidated financial statements	10
(Note on entity's ability to continue as going concern)	10
(Notes on change in scope of consolidation or scope of application of equity method)	10
(Notes in the case of significant changes in amount of shareholders' equity)	10
(Segment Information, etc.)	11
(Revenue recognition)	12
(Significant subsequent events)	13

1. Qualitative information on semi-annual financial results

(1) Explanation of operating results

In the fiscal year ending June 30, 2026, the Asahi Intecc Group (the Group) aims to maintain a high level of growth and further enhance its corporate value by steadily promoting the growth strategies set forth in its new medium-term management plan, "Building the Future 2030," which begins in the fiscal year ending June 30, 2026.

The Group's performance for the six months ended December 31, 2025 progressed favorably, as follows.

Net sales amounted to 71,266 million yen (an increase of 15.9% year on year), driven by the strong performance of both the Medical and Device Divisions.

Gross profit totaled 50,311 million yen (an increase of 21.1% year on year), due to the increase in net sales and improvement in the gross profit margin in line with productivity improvements.

Operating profit was 24,372 million yen (an increase of 40.1% year on year), despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the U.S., as well as an increase in R&D expenses.

Ordinary profit was 24,143 million yen (an increase of 43.5% year on year), due to a decrease in foreign exchange losses.

Profit attributable to owners of parent was 17,214 million yen (an increase of 40.4% year on year), due to an increase in extraordinary income resulting from gain on sales of investment securities.

Foreign exchange rates used for the six months ended December 31, 2025:

150.74 yen per U.S. dollar (151.00 yen for the same period of the previous fiscal year, down 0.2%)

175.79 yen per euro (163.37 yen for the same period of the previous fiscal year, up 7.6%)

21.15 yen per Chinese yuan (21.00 yen for the same period of the previous fiscal year, up 0.7%)

4.68 yen per Thai baht (4.39 yen for the same period of the previous fiscal year, up 6.6%)

The operating results for each segment are outlined below.

<Medical Division>

In the Medical Division, net sales increased in all regions, both in Japan and overseas.

In the domestic market, net sales increased mainly due to strong performance of purchased peripheral vascular products in the non-cardiovascular field.

In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields. In the cardiovascular field, net sales increased primarily for PCI guide wires in all regions.

In the non-cardiovascular field, although sales of neurovascular and abdominal products decreased in the Chinese market, net sales increased overall due to strong sales of peripheral vascular and abdominal products in the U.S., Europe, and Asia.

As a result, net sales totaled 62,665 million yen (an increase of 12.4% year on year).

Segment profit amounted to 23,948 million yen (an increase of 29.3% year on year).

<Device Division>

In the Device Division, net sales increased in both medical and industrial components.

In addition, from the current fiscal year, Nitta Mold was included in the scope of consolidation as a consolidated subsidiary, and the company's profit and loss were reflected in the Group's consolidated results.

As for medical components, net sales increased mainly due to an increase in transactions in cardiovascular inspection catheter components for U.S. companies and the consolidation of Nitta Mold as a subsidiary.

As for industrial components, net sales increased mainly due to an increase in leisure-related transactions in the overseas market and the consolidation of Nitta Mold as a subsidiary.

As a result, net sales totaled 8,600 million yen (an increase of 50.2% year on year).

Segment profit amounted to 4,392 million yen (an increase of 78.7% year on year), mainly due to an increase in revenues from external customers.

(2) Explanation of financial position

As of December 31, 2025, total assets amounted to 195,870 million yen, an increase of 2,682 million yen from the end of the previous fiscal year.

This was mainly due to an increase of 3,025 million yen in buildings and structures, net and an increase of 1,415 million yen in work in process, despite a decrease of 1,656 million yen in construction in progress.

As for liabilities, total liabilities amounted to 37,198 million yen, a decrease of 4,635 million yen from the end of the previous fiscal year. This was mainly due to decreases of 5 million yen in short-term borrowings, 1,187 million yen in long-term borrowings, and 1,128 million yen in provision for bonuses.

As for net assets, total net assets amounted to 158,671 million yen, an increase of 7,317 million yen from the end of the previous fiscal year. This was mainly due to recording 17,214 million yen in profit attributable to owners of parent, despite the purchase and cancellation of treasury shares.

(3) Explanation of forecasts including consolidated results forecast

In addition to the strong performance of both the Medical Division and the Device Division, the exchange rates have remained at higher levels for foreign currencies than initially assumed at the beginning of the fiscal year. Accordingly, the Company made an upward revision to its full-year forecast for net sales, operating profit, ordinary profit, and profit attributable to owners of parent. For details, please refer to “Notice Regarding Revision (Upward Revision) of Full-Year Consolidated Financial Results Forecast for the Fiscal Year Ending June 30, 2026” announced on February 13, 2026.

2. Semi-annual consolidated financial statements and major notes

(1) Semi-annual consolidated balance sheet

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Six months under review (December 31, 2025)
Assets		
Current assets		
Cash and deposits	54,200	53,500
Notes and accounts receivable - trade	15,767	16,652
Electronically recorded monetary claims - operating	2,026	2,036
Merchandise and finished goods	9,408	9,167
Work in process	8,785	10,201
Raw materials and supplies	6,458	7,111
Other	7,004	6,194
Allowance for doubtful accounts	-291	-306
Total current assets	103,359	104,558
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	32,523	35,548
Other, net	26,559	25,328
Total property, plant and equipment	59,082	60,876
Intangible assets		
Goodwill	110	60
Other	5,485	5,393
Total intangible assets	5,595	5,453
Investments and other assets		
Investment securities	19,389	19,600
Other	5,760	5,381
Total investments and other assets	25,149	24,981
Total non-current assets	89,827	91,311
Total assets	193,187	195,870

(Million yen)

	Previous consolidated fiscal year (June 30, 2025)	Six months under review (December 31, 2025)
Liabilities		
Current liabilities		
Notes and accounts payable – trade	2,655	2,633
Electronically recorded obligations - operating	424	693
Short-term borrowings	2,387	2,381
Income taxes payable	4,789	5,490
Provision for bonuses	2,868	1,740
Other	14,730	9,421
Total current liabilities	27,856	22,359
Non-current liabilities		
Long-term borrowings	6,633	5,446
Provision for retirement benefits for directors (and other officers)	19	19
Retirement benefit liability	2,943	3,336
Asset retirement obligations	197	200
Other	4,182	5,835
Total non-current liabilities	13,976	14,838
Total liabilities	41,833	37,198
Net assets		
Shareholders' equity		
Share capital	18,860	18,860
Capital surplus	21,779	18,872
Retained earnings	97,947	96,573
Treasury shares	-4,453	-18
Total shareholders' equity	134,134	134,287
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,008	2,228
Foreign currency translation adjustment	14,315	21,192
Remeasurements of defined benefit plans	99	67
Total accumulated other comprehensive income	16,424	23,488
Non-controlling interests	795	896
Total net assets	151,354	158,671
Total liabilities and net assets	193,187	195,870

(2) Semi-annual consolidated statements of income and comprehensive income
Semi-annual consolidated statement of income

	(Million yen)	
	Previous six months period (from July 1, 2024 to December 31, 2024)	Six months under review (from July 1, 2025 to December 31, 2025)
Net sales	61,491	71,266
Cost of sales	19,941	20,955
Gross profit	41,549	50,311
Selling, general and administrative expenses	24,154	25,939
Operating profit	17,395	24,372
Non-operating income		
Interest income	48	100
Dividend income	81	48
Subsidy income	155	122
Other	157	85
Total non-operating income	442	356
Non-operating expenses		
Interest expenses	181	78
Foreign exchange losses	784	319
Other	51	187
Total non-operating expenses	1,016	585
Ordinary profit	16,821	24,143
Extraordinary income		
Gain on sale of investment securities	23	629
Reversal of allowance for doubtful accounts	100	-
Total extraordinary income	123	629
Extraordinary losses		
Loss on sale of investment securities	-	6
Total extraordinary losses	-	6
Profit before income taxes	16,945	24,766
Income taxes - current	5,008	5,953
Income taxes - deferred	-355	1,560
Total income taxes	4,652	7,514
Profit	12,293	17,252
Profit attributable to non-controlling interests	31	38
Profit attributable to owners of parent	12,261	17,214

Semi-annual consolidated statement of comprehensive income

(Million yen)

	Previous six months period (from July 1, 2024 to December 31, 2024)	Six months under review (from July 1, 2025 to December 31, 2025)
Profit	12,293	17,252
Other comprehensive income		
Valuation difference on available-for-sale securities	-426	219
Foreign currency translation adjustment	640	6,938
Remeasurements of defined benefit plans, net of tax	-6	-32
Total other comprehensive income	207	7,126
Comprehensive income	12,501	24,378
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	12,475	24,278
Comprehensive income attributable to non-controlling interests	25	100

(3) Semi-annual consolidated statement of cash flows

(Million yen)

	Previous six months period (from July 1, 2024 to December 31, 2024)	Six months under review (from July 1, 2025 to December 31, 2025)
Cash flows from operating activities		
Profit before income taxes	16,945	24,766
Depreciation	4,693	4,461
Increase (decrease) in provision for bonuses	-1,084	-1,200
Interest expenses	181	78
Amortization of goodwill	622	57
Decrease (increase) in trade receivables	772	390
Decrease (increase) in inventories	2,599	1,213
Increase (decrease) in trade payables	41	-278
Decrease (increase) in consumption taxes refund receivable	1,327	176
Increase (decrease) in accounts payable - other	-688	82
Decrease (increase) in accounts receivable – other	148	-58
Increase (decrease) in advances received	-4,293	-6,060
Other, net	272	-558
Subtotal	21,537	23,069
Interest and dividends received	145	161
Interest paid	-210	-78
Income taxes paid	-3,188	-5,369
Net cash provided by (used in) operating activities	18,284	17,783

(Million yen)

	Previous six months period (from July 1, 2024 to December 31, 2024)	Six months under review (from July 1, 2025 to December 31, 2025)
Cash flows from investing activities		
Purchase of property, plant and equipment	-4,035	-2,372
Purchase of intangible assets	-214	-201
Purchase of investment securities	-3,074	-2,062
Proceeds from sale of investment securities	23	2,788
Other, net	287	889
Net cash provided by (used in) investing activities	-7,013	-957
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	-507	-
Proceeds from long-term borrowings	2,000	-
Repayments of long-term borrowings	-4,622	-1,193
Dividends paid	-5,533	-6,534
Purchase of treasury shares	0	-10,553
Repayments of lease liabilities	-206	-305
Net cash provided by (used in) financing activities	-8,869	-18,586
Effect of exchange rate change on cash and cash equivalents	-495	1,607
Net increase (decrease) in cash and cash equivalents	1,906	-152
Increase (decrease) in cash and cash equivalents resulting from change in scope of consolidation	-	452
Cash and cash equivalents at beginning of period	35,658	53,200
Cash and cash equivalents at end of period	37,564	53,500

(4) Notes to semi-annual consolidated financial statements

(Note on entity's ability to continue as going concern)

Not applicable.

(Notes on change in scope of consolidation or scope of application of equity method)

During the six months ended December 31, 2025, Nitta Mold Co., Ltd. and its subsidiary, NITTA M&T (THAILAND) CO., LTD., were included in the scope of consolidation.

(Notes in the case of significant changes in amount of shareholders' equity)

(Purchase of treasury shares)

Based on the resolution of the Board of Directors' meeting held on May 15, 2025, the Company acquired 4,344,600 shares of treasury shares during the six months ended December 31, 2025. As a result, treasury shares increased by 10,553 million yen.

(Cancellation of treasury shares)

Based on the resolution of the Board of Directors' meeting held on May 15, 2025, the Company cancelled 6,301,300 shares of treasury shares during the six months ended December 31, 2025 pursuant to Article 178 of the Companies Act.

As a result, capital surplus decreased by 2,907 million yen, retained earnings decreased by 12,080 million yen, and treasury shares decreased by 14,988 million yen. Capital surplus amounted to 18,872 million yen, retained earnings amounted to 96,573 million yen, and treasury shares amounted to 18 million yen as of December 31, 2025.

(Segment Information, etc.)

[Segment Information]

I Six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per semi-annual consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	55,763	5,727	61,491	–	61,491
Transactions with other segments	–	7,288	7,288	-7,288	–
Total	55,763	13,016	68,780	-7,288	61,491
Segment profit	18,518	2,457	20,976	-3,581	17,395

- Notes: 1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
2. Segment profit is adjusted with the operating profit in the semi-annual consolidated statement of income.

II Six months ended December 31, 2025 (from July 1, 2025 to December 31, 2025)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

	Reportable segment			Adjustments (Note 1)	Per semi-annual consolidated financial statements (Note 2)
	Medical Division	Device Division	Total		
Net sales					
Revenues from external customers	62,665	8,600	71,266	–	71,266
Transactions with other segments	–	8,321	8,321	-8,321	–
Total	62,665	16,922	79,588	-8,321	71,266
Segment profit	23,948	4,392	28,341	-3,969	24,372

- Notes: 1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
2. Segment profit is adjusted with the operating profit in the semi-annual consolidated statement of income.

(Revenue recognition)

Disaggregation of revenue from contracts with customers

(1) Breakdown by type

Six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	42,390	–	42,390
Non-cardiovascular	9,506	–	9,506
OEM	3,866	–	3,866
Medical Components	–	3,787	3,787
Industrial Components	–	1,940	1,940
Total	55,763	5,727	61,491

Six months ended December 31, 2025 (from July 1, 2025 to December 31, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Cardiovascular	47,450	–	47,450
Non-cardiovascular	11,299	–	11,299
OEM	3,916	–	3,916
Medical Components	–	5,419	5,419
Industrial Components	–	3,181	3,181
Total	62,665	8,600	71,266

(2) Breakdown by region

Six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	7,866	1,396	9,262
North America	11,130	1,786	12,916
Europe	11,555	232	11,788
China	16,546	257	16,804
Others	8,664	2,054	10,718
Total	55,763	5,727	61,491

Six months ended December 31, 2025 (from July 1, 2025 to December 31, 2025)

(Million yen)

	Reportable segment		
	Medical Division	Device Division	Total
Japan	8,307	1,927	10,235
North America	12,309	2,757	15,066
Europe	13,918	279	14,198
China	18,976	346	19,323
Others	9,153	3,289	12,443
Total	62,665	8,600	71,266

(Significant subsequent events)

Not applicable.